SCHEMBL4721049

SCHEMBL4721049

COc1ccc2ccccc2c1-c1[c]nns1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
NISCH Q9Y2I1 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
NQO1 P15559 1/20 0.38
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2C9 P11712 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.35
CETP P11597 1/20 0.35
HIF1A Q16665 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723532 0.85 ALOX5 (0.51) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL4722242 0.83 MEN1 (0.43) MAPTKMT2AMEN1
SCHEMBL4765411 0.82 GAA (0.48) MAPTKMT2AMEN1CYP2C9
SCHEMBL998182 0.76 MAPT (1.00) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL29428410 0.76 MAPT (1.00) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL4724591 0.74 MAPT (0.62) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL4723433 0.72 MAPT (0.60) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL4724808 0.72 APP (0.46) MAPTKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL22534454 0.71 MAPT (0.88) MAPTKMT2AMEN1NISCHSMN1; SMN2
SCHEMBL31336201 0.71 MAPT (0.88) MAPTKMT2AMEN1NISCHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 MAPT 4361/4885KMT2A 3345/4885MEN1 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.